TRIAGE OF THE ED PATIENT COMPLAINING OF CHEST PAIN David Plaut Snow, 2004.

Slides:



Advertisements
Similar presentations
Patient Oriented Therapy Non STE ACS
Advertisements

ASSENCE Assessment of cost-effectiveness of Several Strategies of Early diagnosis in patients with acute chest pain and Non Conclusive Electrocardiogram.
Ozone Level ppb (parts per billion)
History and Examination Liz Hinton 14 February 2008
Approach to The Low Risk Chest Pain Patient John P Erwin, III, MD, FACC, FAHA Associate Professor of Medicine Scott and White Heart and Vascular Institute.
Utilization of Cardiac Serum Marker Measurements to Identify and Exclude Acute Myocardial Infarction Francis M. Fesmire, MD, FACEP Assistant Professor,
The Macstrak Project ER Case Studies The following is a series of case studies to review different patient types and how they are captured on the form.
Biochemical Markers for Diagnosis of Myocardial Infarction.
Acute Coronary Syndromes Jason Ryan, M.D.. Acute Coronary Syndromes Unstable Angina + Non-ST-Elevation MI + ST-Elevation MI Acute Coronary Syndromes (ACS)
Acute Coronary Syndrome
1 Lecture | Dr. Usman Ghani
Local improvement following national clinical audit workshops Auditing heart attacks Saving lives Dr Andrew Wragg Barts Health.
Early assessment of myocardial injury by joint measurement of TnT-hs and Copeptin (1) J. Teixeira, (2) P. Wotquenne, (2) V. D’Orio, (3) D. Gruson, (1)
The Macstrak Project ER Case Studies The following is a series of case studies to review different patient types and how they are captured on the form.
Tobias Reichlin, W. Hochholzer, C. Stelzig, K. Laule, M. Potocki, K
Acute coronary syndrome : Risk stratification – markers of myocardial necrosis Paul Calle Emergency Department Ghent University Hospital Belgium.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Overly concerning and falsely reassuring?? FRAMINGHAM RISK FACTORS IN THE ED.
ECG s of patients with acute coronary syndrome Dr. David Tran A&E dept. FVH Year 2009.
ACUTE CORONARY SYNDORME EARLY RISK STRATIFICATION Sarah Jamison March 2003.
Acute Chest Pain “Can I go back to sleep?” Dr. Hussam Al-Faleh Residents Course.
Update on the Medical Management of Acute Coronary Syndrome.
Myocardial infarction biomarkers Lecture 5. Cases 1 Middle aged man referred by family doctor to a dermatologist because of extensive yellow papules with.
Acute Coronary Syndrome. Acute Coronary Syndrome (ACS) Definition of ACS Signs and symptoms of ACS Gender and age related difference in ACS Pathophysiology.
Biochemical Markers of Myocardial Infarction
Enzyme Case Studies: 1 A 67 year old male two days after sustaining multiple injuries in a motor vehicle accident complains of chest pain. There is no.
Ischemic Heart Disease CVS3 Hisham Alkhalidi. Ischemic Heart Disease A group of related syndromes resulting from myocardial ischemia.
APPROACH TO CHEST PAIN. OBJECTIVES  1. Establish a differential diagnosis for chest pain  2. Know what clues to obtain on history to rule-in or out.
Sex-Specific Chest Pain Characteristics in AMI Jay Mansfield, Pgy-3 July 22, 2014 LSU Journal Club Gimenez, M, et. Al. Jama Int Med. 2014;174(2):
Please press F5 on your keyboard to enter presentation mode Welcome to the Eastern Health Pathology guide to hsTnT. The information in this presentation.
ANGINA IS CHEST PAIN OR DISCOMFORT THAT HAPPENS WHEN AN AREA OF YOUR HEART MUSCLE DOESN'T GET ENOUGH OXYGEN-RICH BLOOD.
Biochemical Markers for Diagnosis of Myocardial Infarction Cardiovascular Block Medical Biochemistry Course Dr. Reem M. Sallam, MD, PhD.
ACUTE CORONARY SYNDROMES Part I. Definition Acute coronary syndrome (ACS) describes a spectrum of clinical conditions ranging from ST segment elevation.
Biochemical Investigations In Heart Disaeses
Enzymes, Cardiac Markers, Hepatic Tests clinically useful enzymes: tissue sources preanalytical variables affecting enzyme activities isoenzymes myocardial.
Ischaemic Heart Disease CASE A. CASE A: Mr HA, aged 60 years, was brought in to A&E complaining of chest pain, nausea and a suspected AMI.
Implementation of a Sensitive Troponin I Assay and Risk of Recurrent Myocardial Infarction and Death in Patients With Suspected Acute Coronary Syndrome.
Biochemical Markers of Myocardial Infarction
Spectrum of Acute Coronary Syndromes: Laboratory Findings in Q-Wave AMI Creatine kinase evidence of necrosis NonePositive ECG early ST-segment depression.
Chest Pain Advanced Diagnostic Protocol “ADP”. What is it?  The ADP is simply a pathway that can be used to help standardize the care of patients with.
Biochemical Markers for Diagnosis of Myocardial Infarction
Ischemic Heart Disease CVS3 Hisham Alkhalidi. Ischemic Heart Disease A group of related syndromes resulting from myocardial ischemia.
Cost Conscious Project: How Many Troponins Does It Take? Rola Khedraki.
Cost Containment: Use of Troponin testing in the Inpatient Wards Setting Neal Kaushal, R2 DSR2, May 2013.
Ischaemic heart disease. Coronary artery disease(CAD) is the leading cause of death worldwide. The rates of mortality and disability due to CAD are increasing.
Biochemical Investigations In Heart Disaeses
Biochemistry MI Biomarkers Important. Extra Information.
Cardiac enzymes. 2 – Non enzyme proteins The Troponins
Ischemic Heart Disease
CORONARY ARTERY DISEASE
Emergency Department Conference ECG / Cardiology Case Presentations
Tobias Reichlin, M. D. , Willibald Hochholzer, M. D
Biochemical Markers of Myocardial Infarction
Cost Effective Use of Troponin to Rule Out Acute Coronary Syndrome
Volume 98, Issue 5, Pages (November 1990)
Cardiac Troponin.
Diagnostic Algorithms for ACS and High-Sensitivity Troponin
Chapter 28 Management of Patients With Coronary Vascular Disorders
Cardiac enzymes and cardiac proteins
Section A: Introduction
Part I: A Sensible Approach to Sensitive Troponin
Learning Objectives Current Practices in Ruling Out AMI.
Advancing Acute Coronary Syndrome Assessment:
Cardiac enzymes. 2 – Non enzyme proteins The Troponins
TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
Undetectable High Sensitivity Cardiac Troponin T Level in the Emergency Department and Risk of Myocardial Infarction Nadia Bandstein, MD; Rickard Ljung,
High Sensitivity Troponin (hsTnT) : Result Interpretation Matrix*
Biochemical Markers of Myocardial Infarction
Study flow chart and diagnosis at discharge from ED
Presentation transcript:

TRIAGE OF THE ED PATIENT COMPLAINING OF CHEST PAIN David Plaut Snow, 2004

TRIAGE OF THE ED PATIENT COMPLAINING OF CHEST PAIN AMI-DIAGNOSTIC ECG AMI-NON DIAGNOSTIC ECG Questionable Admissions 30% Questionable Admissions 30% ~4% AMI ND-ECG ~4% AMI ND-ECG NO AMI NO AMI 100% 90% 5,000,000 PATIENTS ADMITTED 500,000 PATIENTS SENT HOME 0% CAP TODAY 1:51, 1994 Unstable angina, stable angina and other acute coronary syndromes 30% Unnecessary Admissions 30%

(GISSI-3 STUDY POPULATION) Time to Presentation PERCENT OF PATIENTS ONSET TO PRESENTATION (HOURS) Note: 50 % present within 4 Hours

Temporal Pattern of Cardiac Markers

Reference Range lie on a continuuuuum TCK > 180 CK-MB > 5 Myo > 80 Age? Sex? Muscle mass? Genes ?

cTn Reference Value. Normal Value for cTnI 0.0

Case A h <0.06<80<2.5<5.0<200 cTnI MYO RIMB TCKTime A 40 yr old male with CP for 2 hours. His ECG was non-diagnostic.

Case A h <0.06<80<2.5<5.0<200 cTnI MYO RIMB TCKTime A 40 yr old male with CP for 2 hours. His ECG was non-diagnostic. DCosta et al. found a negative predictive value of 100% of Myo. at 2 hours. This was confirmed by Kircher and Montague.

Case B A 76 yr old male with a history of IHD and mild CHF. Presents with severe chest pain which did not diminish with nitroglycerin. Time MYO cTnI <80 < h 66 <0.06

Case B A 76 yr old male with a history of IHD and mild CHF. Presents with severe chest pain which did not diminish with nitroglycerin. TimeMYOcTnI 0 h66< As many as 34% AMI present with a normal cardiac profile.

Case B A 76 yr old male with a history of IHD and mild CHF. Presents with severe chest pain which did not diminish with nitroglycerin. TimeMYOcTnI 0 h66< As many as 34% AMI present with a normal cardiac profile.

Case C h <0.06 <80<2.5<5.0<200 cTnIMYO RI MB TCKTime A 48 yr old male complained of CP after working in his field all morning. After trying Maalox he presented to the ED the following morning. Ladenson has found that cTnI remains detectable for as long as 15 days following an AMI.

Case D h <0.06<80<2.5<5.0<200 cTnI MYO RIMB TCK Time A 64 yr old female with known chronic renal failure presents to the ED with some pain in my chest. Her EKG was non-diagnostic. Final diagnosis: Renal failure

Case E h <0.06 <80<2.5<5.0<200 cTnIMyo RICK-MB TCKTime A 83 yr old female with intermittent chest discomfort is admitted to the ED at Huntington Hospital in Pasadena, CA.

Case E h <0.06 <80<2.5<5.0<200 cTnIMyo RICK-MB TCKTime A 83 yr old female with intermittent chest discomfort is admitted to the ED at Huntington Hospital in Pasadena, CA. Final diagnosis: AMI with extension

Questions Which marker(s)? When?

A 6 hour protocol for chest pain evaluation n = 292 (239 non-MI, 53 MI) Sensitivity: 97.2%, specificity: 93% The negative predictive value: 99.6% The six hour rule-out protocol is… accurate and efficacious. Herren, BMJ 2001 Aug 18; 323:372.

A 90 minute accelerated critical pathway for chest pain evaluation All AMIs were diagnosed within 90 min. Negative predictive value: 100% Ninety percent of patients with negative cardiac markers and a negative ECG at 90 minutes were discharged home Ng, S., Am J Cardiol 2001 Sept 15;88(6) n = 1285

Evaluation of a 90 minute protocol Sensitivity: 96.9% Negative predictive value: 99.6% Addition of CK-MB did not improve the sensitivity or the NPV Addition of a 3 hour draw did not improve sensitivity or the NPV McCord, Circulation.2001 Sept 25;104(13): n= 817

Suggested Protocol T 0 Draw sample for cTn (and Myo?) If cTn is diagnostic discontinue order If cTn is not diagnostic Draw 2nd sample hrs. later If cTn is diagnostic discontinue order If cTn is not diagnostic Draw 3d sample hrs. later

TRIAGE OF ED PATIENTS COMPLAINING OF CHEST PAIN CAP TODAY 1:51, 1994 Unstable angina, stable angina and other acute coronary syndromes ~ 30%

Unstable angina is a time bomb … A 68 yr old male with SOB, known chronic renal failure and acute renal insufficiency presents to the ED. His EKG was non-diagnostic. TimecTnI 0 h Final diagnosis: Renal failure with CAD. Patient was discharged.

waiting to EXPLODE ! TimecTnI Three weeks later patient returned with severe chest pain and radiating left arm pain.

Serum cardiac troponin I values in unstable angina. 74 patients with chest pain at rest, electrocardiographic evidence of myocardial ischemia, and normal values of CK-MB Death or nonfatal myocardial infarction was more frequent in patients with elevated cTnI (27.7% vs 5.3%) than those with normal values. Ottani F Am Heart J 1999 Feb;137(2):284-91

cTnI to Predict Risk of Mortality in ACS Antman et al. NEJM 1996; 335:1342-9

TRIAGE OF ED PATIENTS COMPLAINING OF CHEST PAIN CAP TODAY 1:51, 1994 Unstable angina, stable angina and other acute coronary syndromes ~ 30%

28 35% of CHDoOccurs in people with TC <200 mg/dL Adapted from Castelli. Atherosclerosis. 1996;124(suppl):S1-S No CHD Total Cholesterol (mg/dL) Framingham Heart Study26-Year Follow-up CHD Total Cholesterol Distribution: CHD vs. Non-CHD Population

Questions: Why add another test? Why should it be hs-CRP?

30 Is there clinical evidence that hs-CRP, a marker of low grade vascular inflammation, predicts future coronary events?

31 hs-CRP and Risk of Future MI in Apparently Healthy Men P<0.001 P=0.03 Quartile of hs-CRP (range, mg/dL) P Trend <0.001 < – – – – Relative Risk of MI Ridker. N Engl J Med. 1997;336:973–

32 hs-CRP and Risk of Future Cardiovascular Events in Apparently Healthy Women Quartile of hs-CRP (range, mg/dL ) Relative Risk Ridker. Circulation. 1998;98:731–733. P Trend <0.002 < – – – –0.73 > 0.73 > Any event MI or stroke

33 hs-CRP Adds to Predictive Value of TC:HDL Ratio in Determining Risk of First MI TC:HDL Ratio Ridker. Circulation. 1998;97:2007–2011. hs-CRP Relative Risk

34 Is there clinical evidence that the effect of hs-CRP on cardiovascular risk can be modified by preventive therapies?

hs-CRP, Aspirin, and Risks of Future Myocardial Infarction Placebo Aspirin Relative Risk Myocardial Infarction Quartile of C-Reactive Protein Ridker PM, N Engl J Med 1997;336:973-9

What are the recommended guidelines for the use of hs-CRP assays?

Guidelines for Use of hs-CRP the writing group recommends against screening the entire adult population for hs-CRP…. it is reasonable to measure hs-CRP as an adjunct…to further assess absolute risk for CAD primary prevention. Circulation 107 (Jan) 499, 2003

Relative Risk and Average hs-CRP hs-CRP < 1.0 mg/L Low Average >3.01 High

The Importance of the D-dimer Assay and Its Use in the Clinical Setting David Plaut

Thromboembolism Incidence & Mortality DVT affects 2 million Americans per year Without treatment, PE mortality ~ 30% With treatment of heparin or TPA, mortality is <2% Only 15-25% of patients suspected of DVT/PE actually have DVT/PE.

What is the role of D-Dimer Assays in PE and DVT?

Causes of Elevated D-dimer Atherosclerosis Trauma Hepatic diseaseDIC Infection Pregnancy InflammationAge Cancer DVT Thrombolytic Rx PE

What is the importance of a negative D-dimer test? If D-Dimer is negative, then there are no clots being dissolved = no DVT or PE The value lies in the ability of d-dimer assays to rule out the Dx of DVT and PE

Clinical policy, College Emergency Physicians, 2003 Patient management recommendations Level A (high clinical certainty) None specified Ann. Emer. Med 41: 257, 2003

Clinical policy, College Emergency Physicians, 2003 Patient management recommendations Level B (moderate) Low pretest probability of PE use the following tests to exclude PE: 1. A negative quantitative d-dimer 2. A negative qualitative d dimer if Wells score 2 or less.

Clinical policy, College Emergency Physicians, 2003 Patient management recommendations Level C (low) Low pretest prob. of PE use the following tests to exclude PE: A negative quantitative d-dimer or a negative qualitative d dimer (when not used with Wells system)

Wells et al. criteria Suspected DVT 3.0 Alternate Dx is less likely than PE3.0 Heart rate > Immobilized or surgery in last 4 wk 1.5 Previous DVT/PE 1.5 Hemoptysis 1.0 Malignancy (treated within is 6 mo.)1.0 Wells, PS et al. Thromb Haemost. 83: 416, 2000

Wells score and probabilities for PE ScoreProbability % >6 67

Use of D dimer to rule out DVT/PE Prevalence = 29% Sensitivity = 99.5 NPV = 99 Specificity = 41 n= 671 Am. J. Resp. Care 156: 492, 1997

Validity of D-dimer for DVT ( Venography) Ten studies with 945 patients Sensitivity = 97% ( 89 – 100) NPV = 97 ( 92 – 100) Specificity = 54 ( 34 – 80) Brill-Edwards, P Thromb. Hemosta. 82: 688, 1999

Validity of D-dimer for PE ( Various) Ten studies with 1329 patients Sensitivity = 99% (93 – 100) NPV = 99 (92 – 100) Specificity = 28 ( 10 – 50) Brill-Edwards, P Thromb. Hemosta. 82: 688, 1999

Hospitalization and Congestive Heart Failure lMajor public health problem worldwide lMost frequent cause of hospitalization in patients older than 65 years lFourth leading cause of adult hospitalization in US lDRG 127 (Congestive Heart Failure): l Primary diagnosis 1,000,000 hospitalizations/ yr l Secondary diagnosis 2,000,000 hospitalizations/ yr.

Total = $38.1 billion (5.4% of total healthcare coats) OConnell JB et al. J Heart Lung Transplant. 1994;13:S107-S112 Hospitalization: The Predominant Contributor to CHF Costs

myocyte pre proBNP (134 aa) proBNP (108 aa) signal peptide (26 aa) secretion NT-proBNP (1-76) BNP (77-108) Release of BNP from Cardiac Myocytes

Total < n mean SD median th % proBNP: Expected Values for Healthy Subjects

Male Femal e Expected values are also gender-dependent (n = 2980) proBNP: Expected Values for Healthy Subjects

Triage® BNP Test Package Insert BNP vs. NYHA Classification (pg/mL)

Cumulative Survival Rates in CHF Patients With Left Ventricular Dysfunction Stratified on Median Plasma BNP Concentration Tsutamoto T. et al. Circulation 1997;96: BNP < 73 pg/ml BNP > 73 pg/ml Months Cumulative Survival (%) p < 0.001

Log BNP (pmol/l) LVEF (%) Y = -0.7, p<0.001 Davis et al. Lancet 1994;343: BNP vs. EF by Echocardiography

Distance (ft) Log BNP (pg/mL) r = Wieczorek S, Wu AHB, et al. Unpublished data BNP vs. Six-Minute Walk Study by Wu et.al.

BNP Concentration and the Degree of CHF Severity BNP Concentration (pg/ml) 186 ± ± ± 266 n = 27 n = 34 n = 36 CHF Severity MildModerateSevere

Ready for Prime Time? Cardiologists and internists may now have a tool with which to determine whether a patient has congestive heart failure and to measure its severity, much as physicians routinely measure serum creatinine in patients with renal disease and perform liver-function tests in patients with hepatic disorders. Kenneth L. Baughman, MD N Engl J Med 2002;347:

THANK YOU!!

Case C h cTnI <0.06 MYO <80 Time A 67 yr old male with a history of cardiac problems presents to the ED with shortness of breath and pain in his left elbow.